Skip to content
TrialMatch
Sign up
Recruiting

Study on the Molecular Mechanism of Berberine to Improve Type 2 Diabetes Mellitus Complicated With Depression

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The incidence of type 2 diabetes with comorbid depression (T2DD) is notably high, characterized by prolonged disease duration and susceptibility to recurrence. The preliminary experiments identified 5-AVAB, a gut microbiota-derived metabolite, as a potential novel biomarker for T2DD progression. Given the absence of existing research in this area, it warrants in-depth investigation. The investigators plan to collect fecal and serum samples from participants with type 2 diabetes and those with T2DD to quantify 5-AVAB levels, as well as conduct in vitro gut microbiota culturing and sequencing studies.

Condition
Diabetes-Related Complications
Tested
No intervention
Sponsor
Affiliated Hospital of Nantong University

Who can join

Age
18 to 65 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 7

  • Minimum age: 18 years
  • Maximum age: 65 years
  • Study condition: Diabetes-Related Complications
  • Aged 18-65 years (including the critical value), regardless of gender;
  • The Con group was diagnosed with type 2 diabetes and had no history of mental disorders such as depression;
  • The T2DD patient group was diagnosed with type 2 diabetes and depression, where depression met the DSM-5 diagnostic criteria for recurrent depression without psychotic symptoms or single-episode MDD, and the total score of the HAMD-17 scale was ≥22 points;
  • The subjects read and fully understood the patient instructions and signed the informed consent form.

Exclusion 9

  • Those who do not meet the inclusion criteria;
  • Those who have not used antibiotics, prebiotics, probiotics, enteral nutrition drugs, etc. within 3 months before diagnosis, and those who do not use antibiotics, prebiotics, probiotics, enteral nutrition drugs, etc. during treatment;
  • Those with progressive serious diseases (such as cancer);
  • Those with severe aphasia, agnosia, and apraxia;
  • Those who have used psychotropic drugs for a long time within 1 month before the study or have received new drug research in the past 3 months;
  • Pregnant or breastfeeding women;
  • Alcoholics or drug addicts;
  • Those with poor mental condition and unable to cooperate;
  • Those who are considered unsuitable for inclusion in the study.

Where

1 site, 1 recruiting

Affiliated Hospital of Nantong University

Nantong, Jiangsu, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.